HomeProductsBuilding BlocksHeterocyclic ScaffoldsAromatic HeterocyclesCAS 1622902-68-4
Chemical structure of CAS 1622902-68-4

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide

CAS No.1622902-68-4
MDL No.MFCD30187577
MFC14H21N5O2S
MW323.42
InChI KeyIUEWXNHSKRWHDY-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1622902-68-4
Product NameN-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide
Heavy Atom Count22Rotatable Bond Count6
Atom Stereo Count0Bond Stereo Count0
HBA5HBD2
TPSA90.980 ŲCharge0
Exact Mass323.14160Complexity751.43
pKa5.875XLogP1.254

Related Articles

Studies related to this compound and its mechanism of action

Spatial proteomics identifies JAKi as treatment for a lethal skin disease.

Nature • Vol. 635, Issue 8040 • 2024
PMID: 39415009PMC: PMC11602713DOI: 10.1038/s41586-024-08061-0

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.

JAMA dermatology • Vol. 156, Issue 8 • 2020
PMID: 32492087PMC: PMC7271424DOI: 10.1001/jamadermatol.2020.1406

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England) • Vol. 396, Issue 10246 • 2020
PMID: 32711801DOI: 10.1016/S0140-6736(20)30732-7

Documentation

Similar Products